Bearing in mind the crucial role for PRK1 and PRK2 in the epigenetic regulation of events associated with prostate tumour progression/metastasis [47, 55], our discovery of the propensity of TPα/TPβ to induce PRK1/PRK2-mediated chromatin remodelling and neoplastic responses in prostate cells is highly significant, and highlights the potential for TPα and/or TPβ as a therapeutic target in the treatment of prostate cancer including CRPC and potentially in other cancers in which aberrant TP:PRK1 and/or PRK2 signalling is implicated. This evidence concerns the gene PKN2 and prostate cancer.